AORT insider exercise/sale — 10,802 shares at $43.67 avg

Rhea-AI Filing Summary

John E. Davis, Chief Commercial Officer of Artivion, Inc. (AORT), exercised 10,802 stock options with an exercise price of $26.24 per share and acquired 10,802 common shares on 08/12/2025. He then sold the same 10,802 shares at a weighted-average price of $43.673, with reported sale prices ranging $43.470–$43.835.

Following these transactions Mr. Davis beneficially owns 208,778 shares. The exercised options were from a grant dated 02/19/2021 that vests 33 1/3% per year and expires 02/19/2027. The filing notes detailed per-price sale information is available upon request.

Positive

• Reporting person exercised 10,802 options at an exercise price of $26.24 per share.
• Shares sold at a weighted-average price of $43.673, with reported sale prices ranging $43.470–$43.835.
• Beneficial ownership after the transactions remained clearly reported at 208,778 shares.
• Options exercised were from a documented grant dated 02/19/2021 with vesting and expiration dates disclosed.

Negative

• The reporting person disposed of 10,802 common shares in the sale reported on the Form 4.
• Following the transactions, there was no net increase in long-term beneficial ownership from this exercise-and-sale sequence.

Insights

Securities Analyst

TL;DR: Officer exercised 10,802 options and sold the same shares, realizing about $17.43 per-share spread (approx. $188k gross).

The filing documents an option exercise followed by an immediate sale of the resulting shares. The exercise price was $26.24 and the weighted-average sale price was $43.673, implying a per-share spread of $17.433. Gross proceeds approximate $472k from the sale and gross intrinsic value realized is roughly $188k before taxes and fees. Beneficial ownership returned to 208,778 shares, indicating no net increase in long-term holdings from these transactions. For investors, this is a routine liquidity event tied to vested options rather than an operational indicator.

Corporate Governance Expert

TL;DR: Transaction aligns with vesting schedule and Form 4 disclosure; it does not alter control or indicate additional insider accumulation.

The options exercised were from a 02/19/2021 grant with a 33 1/3% annual vesting schedule and a 02/19/2027 expiration. The reporting shows full disclosure of exercise and subsequent sale, including a weighted-average sale price and price range. Because the number of shares sold equals the number acquired, beneficial ownership ended at 208,778 shares, consistent with a tax-cover or sell-to-liquidate portion of an option exercise. The Form 4 provides the enumerated details necessary for transparency and regulatory compliance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis John E

(Last) (First) (Middle)

1655 ROBERTS BLVD., NW

(Street)

KENNESAW GA 30144

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		10,802	A	$26.24	219,580	D
Common Stock	08/12/2025		S		10,802	D	$43.673(1)	208,778	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$26.24	08/12/2025		M			10,802	02/19/2021(2)	02/19/2027	Common Stock	10,802	$0	0	D

Explanation of Responses:

1. Reflects weighted average price. Range of prices were between $43.470 to $43.835. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 19, 2021.

Remarks:

	/s/ John E. Davis	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Artivion (AORT) insider John E. Davis report on the Form 4?

John E. Davis reported exercising 10,802 stock options at $26.24 per share on 08/12/2025 and selling 10,802 shares at a weighted-average price of $43.673.

How many Artivion shares does John E. Davis own after these transactions?

After the transactions Mr. Davis beneficially owns 208,778 shares of Artivion.

What was the sale price range reported for the shares sold by the insider?

The filing reports a weighted-average sale price of $43.673 and a price range of $43.470–$43.835.

Which option grant was exercised and what are its key terms?

The exercised options were from a grant dated 02/19/2021, vesting 33 1/3% per year, with an expiration date of 02/19/2027 and exercise price $26.24.

Did the Form 4 disclose the number of derivative securities remaining from the grant?

The filing indicates the specific grant underlying these transactions and shows the related derivative securities information tied to that grant, with the exercised amount listed as 10,802 options converted to common shares.